BioInvent secures full backing for a SEK 430 million rights issue at SEK 1.00 per share, aiming to fund clinical development of its lead assets BI-1808 and BI-1206 through early 2028.
The rights issue of roughly SEK 430 million at SEK 1.00 per share against a November 5 closing price of SEK 3.715 implies massive dilution of about 86.7 percent for non-participating shareholders, with the share count rising to 493,532,715. Full guarantee coverage removes financing risk, but the deep discount (26.6 percent below TERP) and enlarged share base should pressure the price toward TERP.
By approximately 86.7 percent upon full subscription, though you can sell your subscription rights to partially compensate.
SEK 1.00 per new share, roughly a 26.6 percent discount to TERP based on the November 5, 2026 closing price of SEK 3.715.
BioInvent International has finalized terms for a SEK 430 million rights issue, setting the subscription price at SEK 1.00 per share. The offering is fully covered by subscription commitments and guarantee undertakings, providing the biotech firm with a runway into Q1 2028 to advance its clinical programs for solid tumor treatments.
By approximately 86.7 percent upon full subscription, though you can sell your subscription rights to partially compensate.
SEK 1.00 per new share, roughly a 26.6 percent discount to TERP based on the November 5, 2026 closing price of SEK 3.715.